IRCT20150303021315N22已完成2 期
Evaluating the efficacy and safety of Adalimumab in patients with COVID-19
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with the ability to comprehend and willingness to participate in the trial?.
- •Patients who are at least 18 years old at the beginning of trial.
- •Patients with Fever higher than 37.8 C, Cough, shortness of breath accompanied by SpO2 =%93, who ?have a confirmed diagnosis of SARS-CoV-2 infection using RT-PCR.
- •patients with increased level of TNF-alpha to 3 times as much as normal range or with remarkable increase in CRP or Ferritin.
排除标准
- •Patients attending other clinical trials at the same time.
- •patients who are pregnant or breastfeeding.
- •patients with (ALT/AST> 5ULN, ANC <0.5 (x109/L), Platelet count<50 (x109/L) based on laboratory findings.
- •People with active immune-related rheumatic diseases who have been treated with anti-TNF medications for the last 6 months.
- •People taking immunosuppressive drugs.
- •People who are allergic to adalimumab or other components of the formulation of these drugs.
- •People with active pulmonary tuberculosis or other active bacterial or fungal infections (Based on IGRA, procalcitonin and blood culture)
- •People with heart failure (grades 3 and 4 of NYHA).
- •History of demyelinating diseases in the patient or his/her family
研究者
相似试验
已完成
2 期
Evaluating the effects of Adalimumab in patients with acute respiratory distress syndrome caused by COVID-19IRCT20151227025726N23Shahid Beheshti University of Medical Sciences60
已完成
不适用
The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to InfliximabCrohn's Disease patient as following 1)or 2) 1)the patient who treated with IFX infusion of interval every 4-6 weeks. 2)the patient who could not keep to treat with IFX due to side effect or ineffectiveness.JPRN-UMIN000005761Kenji Watanabe50
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-BEAbbott GmbH & Co. KG1,200
进行中（未招募）
1 期
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-DKAbbott GmbH & Co. KG1,200
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYEUCTR2005-004826-21-GRAbbott GmbH & Co. KG1,200